Oxford BioTherapeutics
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
Oxford BioTherapeutics is a clinical-stage oncology company, developing first-in-class antibody-based therapies to improve patient outcomes. Our proprietary, proteomic target discovery platform, OGAP®-Verify, specialises in identifying novel membrane-based protein targets.
Company HQ City:
San Jose
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2004
Lead Product in Development:
Various products based on OGAP database
CEO
Christian Rohlff
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
Q3 2026
Primary Speaker
.jpg/fit-in/500x9999/filters:no_upscale())
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}